Thumbnail for 2024 Annual Meeting On-Demand: FULL ACCESS

2024 Annual Meeting On-Demand: FULL ACCESS

$69900
Standard Price
Members save $100

By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit. This package includes 103 sessions which are eligible for up to:

  • 121.50 General Participation credits, California Nurse contact hours, California Lab Personnel or Florida Lab Personnel contact hours
  • 73.75 Continuing medical education credits for physicians

If purchasing each session individually the cost is $2,615/$3,140 (member/nonmember). Access is available through December 31, 2026 so purchase this package today.

Residents/Fellows/Students – AABB is pleased to offer a reduced rate of $199. Simply email a signed a letter from your institution/Program Director and/or current student transcript verifying your status to eLearning@aabb.org.

Annual meeting attendees - AABB will extend the discounted price of $259/$309 (member/nonmember) for purchase of this package to continue to earn continuing education credits. Contact eLearning@aabb.org to receive a promocode to use to register (Annual Meeting registration will be verified; daily and virtual registrations not eligible).

Purchase of this package includes the on-demand recording and a downloadable MP3 audio file for each session. Some handouts for some speakers may be available. The SBB/BB Exam Review 2024 on-demand session is not included with this package (sold separately).

Program Offering Disclosures:

Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose. All identified conflicts of interest have been mitigated.

Please note: AABB reserves the right to make updates to this program and the offerings within. This program and the recordings are ©2024 AABB, all rights reserved. Reproducing and/or distributing this program or any material within is prohibited.

Products

  • Thumbnail for AM24-ST-01-O: The Use of HLA-Typed Cellular Transfusions and/or Infusions for In Vivo Adsorption of Donor-Specific HLA Antibodies (DSAs) as a Desensitization Strategy for Hematopoietic Stem Cell Transplant Patients (Enduring)
    Date
    October 23, 2024

    CABP CE Eligible 

    Not every hematopoietic stem cell transplant (HSCT) patient will be able to find a 10/10 HLA-matched donor, much less the perfect 12/12 matched donor. In these situations, one can turn to the availability of HLA-mismatched stem cell donors, which include haploidentical related donors, mismatched unrelated donors, and mismatched cord blood stem cells. Over time, we have seen increasing advancements in clinical practice that have moved needle in the direction of equivalent or non-inferior outcomes with mismatched stem cell donor options. The downside of seeing this increasing use of HLA-mismatched donors is that we are also encountering with greater frequency the challenge of donor specific HLA-antibodies (DSAs) in the patient, which put the patient at increased risk for delayed engraftment or even engraftment failure, especially when DSAs are present at high titers. Therefore, there is an ongoing exploration of different desensitization strategies targeted at reducing DSAs to clinically useful levels. These include various approaches directed towards decreasing antibody production and removing DSAs already in circulation, and are often used in combination. One strategy that has emerged, and which is relevant to the transfusion medicine community but not yet well known, is the modality of using HLA-typed platelet and/or leukocyte transfusions/infusions to remove DSAs via “in vivo adsorption”. In this session, Dr. Deanna Fang will first present the HLA-related principles behind this technique and provide a review the evidence presented internationally in literature thus far. Then, Dr. Stefan Ciurea, the director of his institution's Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, will present on his experience with the first known United States-based published and protocolized practice of incorporating HLA-typed cellular infusions as part of an HSCT patient's desensitization regimen. Dr. Minh-Ha Tran will also be present to share his expertise with this protocol from the transfusion medicine physician's perspective with regards to the logistics of donor collection and product processing and issuance.

    Speakers

    Speaker Image for Deanna Fang
    Associate Director, Immunogenetics & Transplantation Laboratory, Transfusion Medicine, UC San Diego School of Medicine
    Speaker Image for Stefan Ciurea
    UNIVERSITY OF CALIFORNIA, IRVINE

    Moderator

    Speaker Image for Minh-Ha Tran
    UCI Apheresis Collection Facility
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-02-O: Laboratory Clinicians and Transfusion Medicine Specialist at the Center of Patient Safety (Enduring)
    Date
    October 23, 2024
    “First do no harm” has been the central dogma of practice of medicine since antiquity and continues to be the guiding principle today. Efforts have been made at local, national and international levels to ensure that patient safety is at the forefront of all aspects of clinical care. Although many of these efforts are led by clinical specialists, the laboratories including the blood bank had been an essential partner in providing objective data and metrics to measure, improve and monitor patient safety. In the past decade as clinical practice evolved, electronic-based medical records became an integral part of documenting and storing patient’s data. It presents opportunities for laboratorians including blood bankers to lead and be the catalyst for new patient safety initiatives. In this session, Dr. James Kelley will present discuss the importance of patient safety programs that were driven by laboratorians and how the use of laboratory results in conjunction with clinical data can improve patient safety. Dr. Kim Klein will share her institution’s first of its kind prospective monitoring programs which utilize state of the art technologies with novel deployment of nursing resources for early detection and prevention of severity transfusion reactions.

    Speakers

    Speaker Image for Kimberly Klein
    M.D. Anderson Cancer Center

    Moderator

    Speaker Image for Marisa Saint Martin
    Loyola University Medical Center
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-03-O: The Importance of Mentors...or The Long and Winding Road (presented by LeeAnn Walker, Sally Frank Memorial Award recipient) (Enduring)
    Date
    October 23, 2024

    Role models and mentors can set the stage for the next generation of Blood Bank/Transfusion Medicine professionals to step up and move our profession forward. In this session, we will examine the benefits of mentoring new employees and students as they begin their careers and throughout the years as they move into various positions. The speaker will share ways that mentoring has shaped her career of almost 50 years, as well as how she, as an educator, has mentored students to grow as laboratory professionals.

    Award Citation: In grateful recognition for her strong leadership and influence on the field of blood banking. LeeAnn Walker has dedicated her career to advancing the field and has been a vital leader in providing education to younger generations. She has passionately shared her expertise and enthusiasm with hundreds of students, passing on knowledge and ensuring the future success of the field; many of her students have gone on to have influential careers as well.

    Moderator

    Speaker Image for Paul Mansfield
    Paul Mansfield, MLS(ASCP)SBB
    Director, IRL, American Red Cross

    Award Presenter

    Speaker Image for Jayanna Slayten
    Jayanna Slayten, MS, MT(ASCP)SBB
    Indiana University Health

    Speaker

    Speaker Image for LeeAnn Walker
    LeeAnn Walker, MEd, MLS(ASCP)SBB
    Associate Professor, The University of Texas Medical Branch, Galveston
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-04-O: THOR-AABB Collaborative Session: Hemostatic Resuscitation Practice for Women, Prehospital Programs, and International Implementation (Enduring)
    Date
    October 23, 2024

    In this joint session organized by the Trauma, Hemostasis and Oxygenation Research (THOR) Network and the Association for the Advancement of Blood and Biotherapies (AABB) Collaborative, the latest evidence and expert opinion on emergency transfusion for females of childbearing potential with life-threatening bleeding, prehospital transfusion and emergency preparedness, and international perspectives on hemostatic resuscitation practice will be presented, including an update on the newly developed AABB Standards for Out of Hospital and Prehospital Administration Transfusion Services. 

    Speakers

    Speaker Image for Alyssa Ziman
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA
    Speaker Image for Molly Sherwood
    Director of Research, Allo Hope Foundation
    Speaker Image for Bryan Cotton
    Bryan Cotton, MD, MPH, FACS
    Memorial Hermann Hospital
    Speaker Image for John Holcomb
    Professor of Surgery, University of Alabama at Birmingham
    Speaker Image for Audra Taylor
    South Texas Blood &Tissue
    Speaker Image for Joanne Pink
    Joanne Pink, MD, FRCPA, FRACP
    Australian Red Cross Lifeblood
    Speaker Image for Vanessa Agostini
    IRCCS Ospedale Policlinico San Martino Genova
    Speaker Image for Daise Muller
    SAMU Aeromédico de Santa Catarina, Brasil

    Moderator

    Speaker Image for Mark Yazer
    University of Pittsburgh
    $6000
    Standard Price
    Members save $10
  • Thumbnail for AM24-ST-05-O: RBC Transfusions for Patients with Hematologic Conditions: Hemoglobin Thresholds, Iron Metabolism (Enduring)
    Date
    October 23, 2024
    Patients with marrow suppression and hypoproliferative anemia represent a challenge for red blood cell transfusions. Iron overload affects the health and quality of life of patients with chronic transfusion needs and patients with primary defects on iron metabolism. In general, patients receiving more than 10 or 20 red blood cell transfusions are at significant risk of developing iron overload. In addition, iron metabolism is disrupted by chemotherapy or hematopoietic cell transplantation used to treat acute leukemias and myelodysplastic syndromes, contributing to the risk of transfusion-related iron overload. Red blood cell transfusion is not without risks and should be used when benefits outweigh the risks. The recent 2023 AABB International RBC guidelines recommended for the first time, a restrictive transfusion threshold for this patient population. Since the 2016 AABB RBC guidelines, several clinical trials evaluating transfusion thresholds in this population were completed, and new evidence became available. Outcomes such as bleeding, exposure to blood and quality of life are of particular importance in patients with marrow suppression and cancer. The purpose of this session is to discuss the effects of transfusion on iron metabolism and outcomes in patients with hematologic/oncologic conditions. We will also review the diagnostic tools, preventive strategies and treatment options for iron overload, and well as the new evidence evaluating hemoglobin thresholds that influence transfusion burden, so the audience can inform their transfusion decisions.

    Speakers

    Speaker Image for Monica Pagano
    Division Head of Transfusion Medicine, Medical Director Transfusion Services, University of Washington
    Speaker Image for Kleber Fertrin
    Fred Hutch Cancer Center

    Moderator

    Speaker Image for Katerina Pavenski
    Haematologist and Head of Transfusion Medicine, University of Toronto
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-06-O: Oral Abstracts - Infectious Diseases, Viruses (Enduring)
    Date
    October 23, 2024
    Oral Abstracts about Infectious Diseases and Viruses

    Speakers

    Speaker Image for Emilya Huseynova
    The American Red Cross
    Speaker Image for Soraya Amar El-Dusouqui
    Swiss Transfusion SRC
    Speaker Image for Fatima Zaman
    Fatima Zaman, MBBS, MPH, MMSc
    Johns Hopkins University
    Speaker Image for Tait Huso
    Johns Hopkins University School of Medicine

    Moderators

    Speaker Image for Ralph Vassallo
    EVP / Chief Medical & Scientific Officer, Vitalant
    Speaker Image for Tobias Cohen
    Tobias Cohen, MD, PhD
    Weill Cornell Medicine
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-07-O: Preparing for the Data Deluge: Mitigating the Informatics Challenges of Expanded RBC Genotyping Data (Enduring)
    Date
    October 23, 2024
    Advances in molecular techniques for Red Blood Cell (RBC) genotyping and phenotyping are improving blood transfusion compatibility significantly for Sickle Cell Disease (SCD) patients and others requiring chronic transfusions. This marks a major milestone in transfusion medicine, offering improved patient-donor matching and better outcomes, while it introduces informatics challenges in using patient genotyping information for donor unit selection from inventory. Expanded RBC phenotyping data—which covers over 1,500 genomic features across more than 40 blood group systems—requires sophisticated data management in Electronic Health Records (EHRs), Blood Bank Laboratory Information Systems (BBLIS), and Blood Establishment Computer Systems (BECS). The current systems used by both hospital blood banks and donor centers do not support this level of substantive interoperability. Improving the informatics surrounding expanded phenotyping and genotyping can amplify the benefits of these molecular approaches and drive increased usage. This presentation will use case studies of SCD patients to highlight the benefits of expanded phenotypes in identifying donor units and expose informatics challenges in integrating and sharing this data. It will outline practical solutions for immediate use and future improvements, with an emphasis on standardized vocabulary, shared semantics, interoperability, and the application of machine learning/artificial intelligence for enhanced donor-patient matching. Collaborative innovation in informatics and standardized practices will establish the foundation for the full potential of molecular genotyping. This talk will guide transfusion medicine professionals in navigating these complexities and ensuring that technological progress in genotyping translates into clinical benefits for patients.

    Speakers

    Speaker Image for Marianne Yee
    Marianne Yee, MD, MSCR
    Emory University and Children's Healthcare of Atlanta
    Speaker Image for John Spinosa
    John Spinosa, MD, PhD
    Lantana Consulting Group

    Moderator

    Speaker Image for Ross Fasano
    Associate Professor, Emory University
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-09-O: Sterility Testing for Cellular Therapies: Updates and Challenges.  What Should We Be Doing? (Enduring)
    Date
    October 23, 2024

    CABP CE Eligible 

    There are core regulations that the use of human cells and tissues must not introduce communicable disease, either from contamination, cross contamination or mix ups. The FDA has clarified that distributing products with objectionable microorganisms is the spread of communicable disease. There are several approaches to sterility testing that include both USP and automated or Rapid Microbiology assays. A review of updates to Sterility Testing requirements for HCTPs (361s) and Biological Products (351s) for procedures or processes that are designed to ensure product sterility will be reviewed in context to FDA requirements and USP Compendial methods. This session will also review common practices and hurdles for implementing the USP sterility testing requirements for these products that have unique constraints such as short product shelf life and sampling size. The panelists will host a discussion session on the similarities and differences between regulatory requirements found in 21 CFR 211.84 (d) (6), 21 CFR 610.12, 21 CFR 1271.1 (a) and 21 CFR 1271.220. An update on several new USP chapters that have direct impact on biologics if they fall into the category of “short shelf-life products”, will also be provided and include: 

    • < 86> Bacterial Endotoxins Test Using Recombinant Reagents 
    • < 72> Respiration Based Methods for Short Shelf-Life Products (aka BacT/ALERT) 
    • < 73> ATP Bioluminescence for Short Shelf-Life Products 
    • < 1071> Rapid Micro Methods 

    Moderator

    Speaker Image for J. Wade Atkins
    J. Wade Atkins, MS, MLS, SBB, CQA, CABP(H)
    NIH/CC/DTM

    Speakers

    Speaker Image for Dr. Anna Lau
    Dr. Anna Lau, PhD, D(ABMM)
    NIH/CC/DTM
    Speaker Image for Elizabeth Lessey-Morillon
    Center for Biologics Evaluation and Research; Office of Therapeutic Products; Office of Cellular Therapy & Human Tissue, CMC; U.S. Food and Drug Administration
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-10-O: Debate: Liberal versus Restrictive Transfusion Strategy in Acute Myocardial Infarction (AABB/ISBT Joint Session) (Enduring)
    Date
    October 23, 2024

    The Myocardial and Ischemia Trial (MINT) was published in December 2023. MINT enrolled 3504 patients with acute myocardial infarction and hemoglobin concentration less than 10 g/dL and randomly allocated participants to either a liberal transfusion strategy that required transfusion to maintain hemoglobin concentration greater than or equal 10 g/dL or a restrictive transfusion strategy that permitted transfusion below 8 g/dL and strongly recommended transfusion below 7 g/dL. The investigators concluded “In patients with acute myocardial infarction and anemia, a liberal transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days. However, potential harms of a restrictive transfusion strategy cannot be excluded.” The clinical implications of this large study continue to be discussed. In addition, this trial data is now being incorporated into meta-analyses together with other trials conducted in the setting of acute myocardial infarction and anemia. Following the successful format of a debate at the 2023 AABB meeting, two speakers will now debate whether anemic patients with acute myocardial infarction should be managed with a liberal or restrictive transfusion strategy, and provide arguments for and against each approach.

    Moderator

    Speaker Image for Simon Stanworth
    Simon Stanworth, DPhil, MD
    Professor of Haematology and Transfusion Medicine; Consultant Haematologist, University of Oxford

    Speakers

    Speaker Image for Jeffrey Carson
    Rutgers Robert Wood Johnson Medical School
    Speaker Image for Aryeh Shander
    Aryeh Shander, MD, FCCM, FCCP, FASA
    Englewood Health
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-11-O: Coverage and Reimbursement Policy 101 for Transfusion Medicine and Cellular Therapies (Enduring)
    Date
    October 23, 2024
    Transfusion physicians, technologists, managers, and support staff need to have at least a basic understanding of billing and coding procedures. Those who are responsible for maintaining appropriate billing and coding need to keep up with the constantly changing expectations for coding and billing. This session is designed to provide a comprehensive overview of current coding and reimbursement information in both the inpatient and outpatient hospital prospective payment systems, including critical updates, as well as share best practices and case studies from hospitals. Coding and reimbursement for CAR-T and newer therapies will also be covered. Medicare advocacy and resources will also be discussed to help hospitals ensure they receive appropriate payment.

    Moderator

    Speaker Image for Susan Leppke
    Senior Director, Public Policy and Strategic Partnerships, AABB

    Speakers

    Speaker Image for Justin Halls
    Justin Halls, MD, MPH
    Phoenix Children's Hospital
    Speaker Image for Richard Gammon
    Medical Director, OneBlood
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-13-O: Oral Abstracts - Storage Lesion (Enduring)
    Date
    October 23, 2024
    Oral abstracts about Storage Lesion.

    Speakers

    Speaker Image for Ute Gravemann
    German Red Cross Blood Service NSTOB
    Speaker Image for DENESE MARKS
    Research Program Leader, Australian Red Cross Lifeblood
    Speaker Image for Susanne Marschner
    Vitalant Research Institute

    Moderators

    Speaker Image for Cristina Figueroa Villalba
    Yale School of Medicine
    Speaker Image for John Hess
    John R. Hess, MD, MPH, FACP, FAAAS
    University of Washington School of Medicine
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-15-O: Sickle Cell Disease Psychosocial Support and Advocacy (Enduring)
    Date
    October 23, 2024

    CABP CE Eligible

    Sickle cell disease (SCD) is a beta hemoglobinopathy caused by a single point mutation that causes a chronic debilitating disease characterized by recurrent pain crises and end organ damage. Various treatment modalities are available such as disease modifying drug therapies, red blood cell transfusions, and stem cell transplantation. In December of 2023, the FDA approved two gene therapies, Casgevy and Lyfgenia, that utilize the patient’s own hematopoietic stem cells (HSCs) as the starting material for genetic modification and subsequent autologous transplantation. The list price for Lyfgenia is set at $3.1 million, while Casgevy will cost $2.2 million, making gene therapies for sickle cell disease one of the most expensive treatments worldwide. Access to this therapy will become a challenge for a lot of patients in the absence of insurance coverage. The successful management of patients with SCD, however, goes beyond medical treatment. Patients who have adequate emotional, mental, and spiritual support have shown a better quality of life. Individuals with chronic diseases have a higher risk of mental disorders which are exacerbated by social/relationship problems. Patients with SCD with severe depressive symptoms experience poorer pain outcomes, lower quality of life, and increased risk of opioid misuse. Participation in religious practices facilitates coping with a chronic illness such as SCD. It provides social support and hopefulness that can help alleviate depressive symptoms. This education session will focus on advocacy for patients with SCD in the era of gene therapy and discuss the benefits of psychosocial support.

    Moderator & Speaker

    Speaker Image for Yvette Tanhehco
    Yvette Tanhehco, MD, PhD, MS, CABP(AABB)
    Director of Cellular Therapy Laboratory, Columbia University Irving Medical Center
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-16-O: Transfusion Support for Xenotransplantation (Enduring)
    Date
    October 23, 2024
    We will share our experience performing xenotransplantation (transplantation of genetically modified pig kidneys into human bodies) and the role of xenotransplantation in the search for new sources of viable organs for people facing life-threatening diseases. The transplant team will review the context and process of xenotransplantation, including histocompatibility testing, and discuss the findings and remaining questions from recent cases. The transfusion medicine team will discuss transfusion needs in this patient population and the approach to providing transfusion support.

    Speakers

    Speaker Image for Victoria Costa
    NYU Langone Health
    Speaker Image for Massimo Mangiola
    NYU Langone Health

    Moderator

    Speaker Image for Timothy Hilbert
    Timothy Hilbert, MD, PhD, JD
    NYU Langone Health
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-17-O: Oral Abstracts - Blood Donor Issues (Enduring)
    Date
    October 23, 2024
    Oral Abstract session about blood donor issues.

    Speakers

    Speaker Image for Tamir Kanias
    Vitalant Research Institute
    Speaker Image for W. Alton Russell
    McGill School of Population and Global Health
    Speaker Image for Ralph Vassallo
    EVP / Chief Medical & Scientific Officer, Vitalant

    Moderators

    Speaker Image for Eric Senaldi
    New York Blood Center
    Speaker Image for Gwendolyn Jones
    Institute for Transfusion Medicine
    $3000
    Standard Price
    Members save $5
  • Thumbnail for AM24-ST-18-O: AABB RBC and Platelet International Guidelines: What is New: Liberally Restrictive and Restrictively Liberal? (Enduring)
    Date
    October 23, 2024

    The AABB continues to update and develop clinical transfusion guidelines as new evidence becomes available. In the past year AABB collaborated with international professional societies and relevant experts to develop and update guidelines for platelets and for RBC transfusions in patients undergoing a myocardial infarction. The platelet effort is the first update since AABB and the International Collaboration for Transfusion Medicine Guidelines (ICTMG) published separate guidelines in 2015. The new guidelines discussed in this section were a collaborative effort between the AABB and ICTMG, and also included other international organizations [[International Collaboration for Transfusion Medicine Guidelines (ICTMG), the International Society of Blood Transfusion (ISBT), and others]. The RBC guideline for patients with myocardial infarction (MI) is the first for this patient population.

    During this session, we will briefly discuss the place of guidelines as a tool for changing transfusion practice and also review the guideline development process using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. Next we will provide an overview of the platelet guidelines with updates to recommendations for specific patient populations, including: hypoproliferative thrombocytopenia; procedures; critical illness; cardiac surgery; and intracranial hemorrhage. We will then review the main clinical trials evaluating red blood cell transfusion thresholds in patients with myocardial infarction and present the results of the meta-analysis and summary of findings for critical outcomes. Finally, the provisional language of the new AABB RBC MI guideline will be discussed.

    Moderator

    Speaker Image for Claudia Cohn
    Chief Medical Officer, Associate Professor of Laboratory Medicine and Pathology, Director, Blood Bank Laboratory, Associate Director, Clinical Laboratories, University of Minnesota

    Speakers

    Speaker Image for Simon Stanworth
    Simon Stanworth, DPhil, MD
    Professor of Haematology and Transfusion Medicine; Consultant Haematologist, University of Oxford
    Speaker Image for Ryan Metcalf
    Section Chief, Transfusion Medicine, ARUP Labs and Utah School of Medicine
    Speaker Image for Monica Pagano
    Division Head of Transfusion Medicine, Medical Director Transfusion Services, University of Washington
    $3000
    Standard Price
    Members save $5

AABB Website and Online Services to Undergo Maintenance Dec. 5-6. Learn more.